Potential uses of polyethylene glycol conjugated recombinant IL-2 in common variable immunodeficiency.
Cunningham-Rundles
C
C
Mount Sinai Medical Center, New York, NY 10029.
Kasbay
K
K
Mayer
L
L
D001402:B-Lymphocytes / Q000276:immunology; D017074:Common Variable Immunodeficiency / Q000276:immunology / Q000628:therapy*; D006433:Hemocyanins / Q000276:immunology; D006801:Humans; D007114:Immunization; D007136:Immunoglobulins / Q000096:biosynthesis; D066298:In Vitro Techniques; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000096:biosynthesis / Q000172:deficiency / Q000627:therapeutic use; D010835:Phytohemagglutinins / Q000494:pharmacology; D011092:Polyethylene Glycols; D013211:Staphylococcus aureus / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D007136:Immunoglobulins; D007376:Interleukin-2; D010835:Phytohemagglutinins; C067245:interleukin-2, polyethylene glycol-modified; D011092:Polyethylene Glycols; D006433:Hemocyanins; C032808:keyhole-limpet hemocyanin